Cambrex Corporation (CBM) Stake Reduced by Swiss National Bank
Swiss National Bank reduced its position in Cambrex Corporation (NYSE:CBM) by 3.1% during the third quarter, Holdings Channel reports. The institutional investor owned 52,900 shares of the company’s stock after selling 1,700 shares during the period. Swiss National Bank owned 0.16% of Cambrex Corporation worth $2,352,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of CBM. Fiera Capital Corp bought a new stake in Cambrex Corporation during the second quarter valued at $23,842,000. American Capital Management Inc. bought a new stake in Cambrex Corporation during the third quarter valued at $15,110,000. EverPoint Asset Management LLC bought a new stake in Cambrex Corporation during the second quarter valued at $15,519,000. Old Mutual Global Investors UK Ltd. increased its stake in Cambrex Corporation by 570.3% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 215,289 shares of the company’s stock valued at $9,571,000 after buying an additional 183,169 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Cambrex Corporation by 6.5% in the second quarter. Vanguard Group Inc. now owns 2,858,572 shares of the company’s stock valued at $147,874,000 after buying an additional 175,578 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.
Shares of Cambrex Corporation (NYSE:CBM) traded up 1.00% during midday trading on Friday, hitting $55.75. 105,834 shares of the company were exchanged. Cambrex Corporation has a one year low of $29.50 and a one year high of $59.41. The stock has a market cap of $1.79 billion, a PE ratio of 29.44 and a beta of 1.95. The stock’s 50-day moving average is $53.27 and its 200-day moving average is $48.81.
Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings data on Friday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.06. The business earned $99.90 million during the quarter, compared to the consensus estimate of $96.07 million. Cambrex Corporation had a net margin of 13.24% and a return on equity of 24.11%. Cambrex Corporation’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.40 EPS. Equities research analysts anticipate that Cambrex Corporation will post $2.70 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Cambrex Corporation (CBM) Stake Reduced by Swiss National Bank” was published by Watch List News and is the propert of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of United States and international copyright law. The original version of this report can be read at http://www.watchlistnews.com/cambrex-corporation-cbm-stake-reduced-by-swiss-national-bank/1060400.html.
CBM has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Cambrex Corporation from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 27th. First Analysis raised shares of Cambrex Corporation from an “equal weight” rating to an “overweight” rating and set a $54.00 price objective for the company in a research report on Monday, November 7th.
In related news, insider Gregory Sargen sold 22,500 shares of the company’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $52.02, for a total transaction of $1,170,450.00. Following the completion of the sale, the insider now directly owns 27,500 shares of the company’s stock, valued at approximately $1,430,550. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Shawn Cavanagh sold 30,000 shares of the company’s stock in a transaction on Wednesday, December 14th. The stock was sold at an average price of $53.58, for a total transaction of $1,607,400.00. Following the sale, the chief operating officer now directly owns 27,658 shares of the company’s stock, valued at $1,481,915.64. The disclosure for this sale can be found here. Corporate insiders own 2.63% of the company’s stock.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.